OpenSecrets.org @OpenSecretsDC
Most of the pharmaceutical industry’s 2022 lobbying efforts took aim at the Inflation Reduction Act. The bill allows for Medicare to negotiate the prices of certain prescriptions, caps out-of-pocket spending for Medicare beneficiaries and insulin costs. https://t.co/T2bO6VxsDe — PolitiTweet.org